Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease
Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease
复制标题
DOI：
10.1016/j.parkreldis.2006.05.005
复制
发表时间：
2007-01-01
影响因子：
4.1
通讯作者：
Bentivoglio, Anna Rita
中科院分区：
文献类型：
--
作者：
Contarino, Maria Fiorella;Pomipili, Maurizio;Bentivoglio, Anna Rita
在肌萎缩侧索硬化症(ALS)或帕金森病(PD)患者中，涎泻是常见且无效的。肉毒杆菌毒素(BTX)作为传统治疗方法的替代出现。我们评估了18例ALS或PD患者在超声引导下腮腺和颌下腺注射BTX-B的疗效和耐受性。在第一周，客观评估(棉卷重量)和主观评估(专用临床评分)都记录了流涎减少(P<；0.01)。据报道，肌萎缩侧索硬化症患者受益时间较短(p<；0.001)，唾液粘稠度较高(7比1)，可能是由于不同的自主神经受累模式所致。BTX-B似乎在减少ALS和PD患者的流涎方面是有效的，但这两种情况下的风险-收益比可能不同。这可能会对临床实践产生影响。(C)2006爱思唯尔有限公司。保留所有权利。
Sialorrhea is frequent and invalidating in patients with amyotrophic lateral sclerosis (ALS) or Parkinson's disease (PD). Botulinum toxin (BTX) emerged as an alternative to traditional treatments. We evaluated efficacy and tolerability of ultrasound-guided BTX-B injections in parotids and submandibular glands in 18 patients with ALS or PD. At I week, both objective (cotton rolls weight) and subjective evaluations (dedicated clinical scales) documented sialorrhea reduction (P < 0.01). ALS patients reported shorter benefit duration (p < 0.001) and higher prevalence of viscous saliva (seven vs one patients), possibly due to different pattern of autonomic involvement. BTX-B seems efficacious in reducing sialorrhea in ALS and PD but the risk-benefit ratio might differ between these two conditions. This might have implications for clinical practice. (c) 2006 Elsevier Ltd. All rights reserved.